Pernix ptx Therapeutics misses by $0.08; misses on revs Reports Q4 net loss of $0.05 per share vs $0.03 CIQ est; revs declined 15% YoY to $18.2 mln vs $23.4 mln CIQ est. Adjusted Earnings before interest, taxes, depreciation and amortization was ~$1.0 mln for the fourth quarter of 2012, compared to adjusted EBITDA of $7.6 mln for the fourth quarter of 2011.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.